Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 3/20 | 0.55 |
| ▸ | DHODH | Q02127 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 4/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3920191 | 0.86 | DHODH (0.58) | CETPDHODHESR2HDAC3HDAC1 | |
| SCHEMBL2957208 | 0.86 | CETP (0.60) | CETPDHODHESR2KDM4ENPC1 | |
| SCHEMBL6216739 | 0.86 | DHODH (0.72) | DHODHESR2MAPTHDAC3HDAC1 | |
| SCHEMBL204097 | 0.85 | DHODH (0.60) | CETPDHODHESR2KDM4ENPC1 | |
| SCHEMBL205602 | 0.85 | CETP (0.61) | CETPDHODHESR2KDM4ENPC1 | |
| SCHEMBL204884 | 0.85 | CETP (0.56) | CETPDHODHESR2KDM4ENPC1 | |
| SCHEMBL9126988 | 0.85 | DHODH (0.70) | CETPDHODHESR2KDM4ENPC1 | |
| SCHEMBL2957776 | 0.84 | DHODH (0.58) | CETPDHODHESR2KDM4ENPC1 | |
| SCHEMBL21794368 | 0.84 | DHODH (0.58) | CETPDHODHESR2KDM4ENPC1 | |
| SCHEMBL2959887 | 0.84 | HTR3A (0.58) | CETPDHODHESR2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| US-7384965-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384965-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384965-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2006-09-14 | — | — | US | disclosed |
| EP-1585726-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063155-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | PPARA, PPARG, PPARD | CETP 1414/4885DHODH 3744/4885ESR2 72/4885 |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | PPARA, PPARG, PPARD | CETP 1384/4885DHODH 3746/4885ESR2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.